Skip to main content
. 2016 Mar 18;6:23372. doi: 10.1038/srep23372

Figure 2. Fluvoxamine suppressed serum-induced lamellipodia formation.

Figure 2

(a) Human GBM cell lines (U87-MG and U251-MG) were serum-starved for 24 h, treated with either vehicle (0.1% DMSO) or fluvoxamine (40 μM) for 15 min, and stimulated with 10% FBS for 15 min. G-actin (green) and F-actin (red) were stained with Alexa Fluor 488-conjugated DNase I and Alexa Fluor 555-conjugated phalloidin, respectively. Arrows indicate lamellipodia. Scale bar, 20 μm. (b) Fluvoxamine inhibited serum-induced lamellipodia formation in a dose-dependent manner. Values are mean ± SEM from 5–14 independent fields. **p < 0.01 compared with vehicle, non-repeated measures ANOVA with Dunnett’s post-hoc test. (c) U87 glioma ruffle formation was inhibited in a dose-dependent manner by fluvoxamine and observed by confocal microscopy with G-actin (green) and F-actin staining (red), as above (a).